Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Stella
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(120 sites)
United States
Banner MD Anderson Cancer Center, Gilbert, Arizona
Beverly Hills Cancer Center, Beverly Hills, California
Cedars-Sinai Medical Center, Beverly Hills, California
City of Hope, Duarte, California
Stanford University School of Medicine, Palo Alto, California
University of California Davis, Sacramento, California
University of California San Diego, San Diego, California
University of California San Francisco, San Francisco, California
Kaiser Permanente - Vallejo, Vallejo, California
Rocky Mountain Cancer Centers, Longmont, Colorado
Yale Cancer Center, New Haven, Connecticut
Medical Oncology Hematology Consultants, Newark, Delaware
Medstar Georgetown University Hospital, Washington D.C., District of Columbia
Florida Cancer Specialists, Fort Myers, Florida
Cancer Care Centers of Brevard, Palm Bay, Florida
Rush Medical College, Chicago, Illinois
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Community Health Network, Indianapolis, Indiana
University of Kansas Medical Center, Westwood, Kansas
Cancer Center of Kansas, Wichita, Kansas
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Tufts Medical Center, Boston, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan